CoChat

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer

Open access
Stein, Alexander, Simnica, Donjete, Schultheiß, Christoph, Scholz, Rebekka, Tintelnot, Joseph, Gökkurt, Eray, von Wenserski, Lisa, Willscher, Edith, Paschold, Lisa, Sauer, Markus, Lorenzen, Sylvie, Riera-Knorrenschild, Jorge, Depenbusch, Reinhard, Ettrich, Thomas J, Dörfel, Steffen, Al-Batran, Salah-Eddin, Karthaus, Meinolf, Pelzer, Uwe, Waberer, Lisa, Hinke, Axel, Bauer, Marcus, Massa, Chiara, Seliger, Barbara, Wickenhauser, Claudia, Bokemeyer, Carsten, Hegewisch-Becker, Susanna, Binder, Mascha · 2021 · Journal for ImmunoTherapy of Cancer
Cited by 67

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background: In patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC), immune checkpoint blockade is ineffective, and combinatorial approaches enhancing immunogenicity need exploration. Methods: We treated 43 patients with predominantly microsatellite stable RAS/BRAF wild-type mCRC on a phase II trial combining chemotherapy with the epidermal growth factor receptor antibody cetuximab and the programmed cell death ligand 1 (PD-L1) antibody avelumab. We performed next-generation gene panel sequencing for mutational typing of tumors and liquid biopsy monitoring as well as digital droplet PCR to confirm individual mutations. Translational analyses included tissue immunohistochemistry, multispectral imaging and repertoire sequencing of tumor-infiltrating T cells. Detected PD-L1 mutations were mechanistically validated in CRISPR/Cas9-generated cell models using qRT-PCR, immunoblotting, flow cytometry, complement-dependent cytotoxicity assay, antibody-dependent cytotoxicity by natural killer cell degranulation assay and LDH release assay as well as live cell imaging of T cell mediated tumor cell killing. Results: Circulating tumor DNA showed rapid clearance in the majority of patients mirroring a high rate of early tumor shrinkage. In 3 of 13 patients expressing the high-affinity Fcγ receptor 3a (FcγR3a), tumor subclones with PD-L1 mutations were selected that led to loss of tumor PD-L1 by nonsense-mediated RNA decay in PD-L1 K162fs and protein degradation in PD-L1 L88S. As a consequence, avelumab binding and antibody-dependent cytotoxicity were impaired, while T cell killing of these variant clones was increased. Interestingly, PD-L1 mutant subclones showed slow selection dynamics reversing on avelumab withdrawal and patients with such subclones had above-average treatment benefit. This suggested that the PD-L1 mutations mediated resistance to direct antitumor effects of avelumab, while at the same time loss of PD-L1 reduced biological fitness by enhanced T cell killing limiting subclonal expansion. Conclusion: The addition of avelumab to standard treatment appeared feasible and safe. PD-L1 mutations mediate subclonal immune escape to avelumab in some patients with mCRC expressing high-affinity FcγR3a, which may be a subset experiencing most selective pressure. Future trials evaluating the addition of avelumab to standard treatment in MSS mCRC are warranted especially in this patient subpopulation. Trial registration number: NCT03174405.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2021-002844

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 67

Metadata

Authors
Stein, A., Simnica, D., Schultheiß, C., Scholz, R., Tintelnot, J., Gökkurt, E., von Wenserski, L., Willscher, E., Paschold, L., Sauer, M., Lorenzen, S., Riera-Knorrenschild, J., Depenbusch, R., Ettrich, T. J., Dörfel, S., Al-Batran, S.-E., Karthaus, M., Pelzer, U., Waberer, L., Hinke, A., Bauer, M., Massa, C., Seliger, B., Wickenhauser, C., Bokemeyer, C., Hegewisch-Becker, S., & Binder, M.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2021-07
Volume
9
Issue
7
Pages
e002844
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3186275360
Cited by
67
References
14
FWCI
3.26
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. https://app.cochat.ai/papers/10.1136/jitc-2021-002844
The paper
Stein, A., Simnica, D., Schultheiß, C., Scholz, R., Tintelnot, J., Gökkurt, E., von Wenserski, L., Willscher, E., Paschold, L., Sauer, M., Lorenzen, S., Riera-Knorrenschild, J., Depenbusch, R., Ettrich, T. J., Dörfel, S., Al-Batran, S.-E., Karthaus, M., Pelzer, U., Waberer, L., . . . Binder, M. (2021). PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2021-002844

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.